Tags

Type your tag names separated by a space and hit enter

Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.

Abstract

BACKGROUND

Sex hormone concentrations are associated with breast cancer risk among women not using postmenopausal hormones (PMH); however, whether a relationship exists among PMH users is unknown. Therefore, we conducted a prospective, nested case-control study within the Nurses' Health Study (NHS) cohort to examine the association between plasma sex hormone concentrations and postmenopausal breast cancer among women using PMH at blood collection.

METHODS

Blood samples were collected from 1989 to 1990. During follow-up through May 31, 2000, 446 women developed breast cancer and were matched by age, date and time of day of blood collection, and fasting status to 459 control subjects (PMH users) who did not develop cancer. We used conditional logistic regression to estimate relative risks (RRs) and 95% confidence intervals (CIs). We compared hormone concentrations of the 459 control subjects with those of 363 postmenopausal NHS participants not taking PMH. All statistical tests were two-sided.

RESULTS

PMH users had statistically significantly higher estradiol, free estradiol, sex hormone-binding globulin, and testosterone, and lower free testosterone concentrations than non-PMH users. Among PMH users, we found modest associations with breast cancer risk when comparing the highest versus lowest quartiles of free estradiol (RR = 1.7, 95% CI = 1.1 to 2.7; P(trend) = .06), free testosterone (RR = 1.6, 95% CI = 1.1 to 2.4; P(trend) = .03), and sex hormone-binding globulin (RR = 0.7, 95% CI = 0.5 to 1.1; P(trend) = .04), but not of estradiol or of testosterone. However, estradiol and free estradiol were statistically significantly positively associated with breast cancer risk among women older than 60 years (RR = 2.8, 95% CI = 1.5 to 5.0; P(trend) = .002 and 2.6, 95% CI = 1.4 to 4.7; P(trend) = .001, respectively) and among women with a body mass index of less than 25 kg/m2 (RR = 1.8, 95% CI = 1.1 to 3.1, P(trend) = .01 and 2.4, 95% CI = 1.4 to 4.0, P(trend) = .003, respectively).

CONCLUSION

Although women using PMH have a different hormonal profile than those not using PMH, plasma sex hormone concentrations appear to be associated with breast cancer risk among PMH users.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. nhsst@channing.harvard.edu

    , , , ,

    Source

    Journal of the National Cancer Institute 97:8 2005 Apr 20 pg 595-602

    MeSH

    Aged
    Body Mass Index
    Breast Neoplasms
    Case-Control Studies
    Confidence Intervals
    Confounding Factors (Epidemiology)
    Estradiol
    Estrogen Replacement Therapy
    Female
    Gonadal Steroid Hormones
    Humans
    Incidence
    Logistic Models
    Middle Aged
    Multivariate Analysis
    Nurses
    Postmenopause
    Prospective Studies
    Risk Assessment
    Sex Hormone-Binding Globulin
    Testosterone
    United States

    Pub Type(s)

    Journal Article
    Research Support, U.S. Gov't, Non-P.H.S.
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    15840882

    Citation

    Tworoger, Shelley S., et al. "Plasma Sex Hormone Concentrations and Subsequent Risk of Breast Cancer Among Women Using Postmenopausal Hormones." Journal of the National Cancer Institute, vol. 97, no. 8, 2005, pp. 595-602.
    Tworoger SS, Missmer SA, Barbieri RL, et al. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst. 2005;97(8):595-602.
    Tworoger, S. S., Missmer, S. A., Barbieri, R. L., Willett, W. C., Colditz, G. A., & Hankinson, S. E. (2005). Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. Journal of the National Cancer Institute, 97(8), pp. 595-602.
    Tworoger SS, et al. Plasma Sex Hormone Concentrations and Subsequent Risk of Breast Cancer Among Women Using Postmenopausal Hormones. J Natl Cancer Inst. 2005 Apr 20;97(8):595-602. PubMed PMID: 15840882.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. AU - Tworoger,Shelley S, AU - Missmer,Stacey A, AU - Barbieri,Robert L, AU - Willett,Walter C, AU - Colditz,Graham A, AU - Hankinson,Susan E, PY - 2005/4/21/pubmed PY - 2005/4/26/medline PY - 2005/4/21/entrez SP - 595 EP - 602 JF - Journal of the National Cancer Institute JO - J. Natl. Cancer Inst. VL - 97 IS - 8 N2 - BACKGROUND: Sex hormone concentrations are associated with breast cancer risk among women not using postmenopausal hormones (PMH); however, whether a relationship exists among PMH users is unknown. Therefore, we conducted a prospective, nested case-control study within the Nurses' Health Study (NHS) cohort to examine the association between plasma sex hormone concentrations and postmenopausal breast cancer among women using PMH at blood collection. METHODS: Blood samples were collected from 1989 to 1990. During follow-up through May 31, 2000, 446 women developed breast cancer and were matched by age, date and time of day of blood collection, and fasting status to 459 control subjects (PMH users) who did not develop cancer. We used conditional logistic regression to estimate relative risks (RRs) and 95% confidence intervals (CIs). We compared hormone concentrations of the 459 control subjects with those of 363 postmenopausal NHS participants not taking PMH. All statistical tests were two-sided. RESULTS: PMH users had statistically significantly higher estradiol, free estradiol, sex hormone-binding globulin, and testosterone, and lower free testosterone concentrations than non-PMH users. Among PMH users, we found modest associations with breast cancer risk when comparing the highest versus lowest quartiles of free estradiol (RR = 1.7, 95% CI = 1.1 to 2.7; P(trend) = .06), free testosterone (RR = 1.6, 95% CI = 1.1 to 2.4; P(trend) = .03), and sex hormone-binding globulin (RR = 0.7, 95% CI = 0.5 to 1.1; P(trend) = .04), but not of estradiol or of testosterone. However, estradiol and free estradiol were statistically significantly positively associated with breast cancer risk among women older than 60 years (RR = 2.8, 95% CI = 1.5 to 5.0; P(trend) = .002 and 2.6, 95% CI = 1.4 to 4.7; P(trend) = .001, respectively) and among women with a body mass index of less than 25 kg/m2 (RR = 1.8, 95% CI = 1.1 to 3.1, P(trend) = .01 and 2.4, 95% CI = 1.4 to 4.0, P(trend) = .003, respectively). CONCLUSION: Although women using PMH have a different hormonal profile than those not using PMH, plasma sex hormone concentrations appear to be associated with breast cancer risk among PMH users. SN - 1460-2105 UR - https://www.unboundmedicine.com/medline/citation/15840882/Plasma_sex_hormone_concentrations_and_subsequent_risk_of_breast_cancer_among_women_using_postmenopausal_hormones_ L2 - https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dji099 DB - PRIME DP - Unbound Medicine ER -